TNXP Stock News & Catalysts – Tonix Pharmaceuticals

FEATURED

Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights

New

Third quarter TONMYA® net sales of approximately $15 million, up 37% from the second quarter Approximately $163 million in cash and cash equivalents as of September 30, 2026 Strategic focus on supporting TONMYA growth

Summary

Nov 9, 2026, 7:00 AM ·Globe Newswire

RECENT

Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference

BERKELEY HEIGHTS, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or "the Company"), a fully integrated, commercial-stage biopharmaceutical company,

Nov 4, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation

BERKELEY HEIGHTS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biopharmaceutical company,

Nov 2, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain

TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studies Tonix commercially launched

Oct 27, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today

Oct 26, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

BERKELEY HEIGHTS, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biopharmaceutical company,

Oct 19, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or "the Company"), a fully integrated, commercial-stage biopharmaceutical company,

Oct 15, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer coverage for TONMYA now reaches

Sep 22, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

BERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biopharmaceutical company,

Sep 8, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biopharmaceutical company,

Sep 2, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered

Aug 10, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today

Aug 5, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027 Long-acting monoclonal antibody TNX-4800 is a rapidly acting alternative to vaccination

Aug 3, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today

Jul 27, 2026, 7:00 AM ·Globe Newswire

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak Three new models for investigating mpox infection and pathogenesis identified Tonix is advancing

Jul 15, 2026, 9:05 AM ·Globe Newswire

Tonix Pharmaceuticals Holding Corp. TNXP · News